

**PROGRESSIVE'S EVENING STROLL**

**DATE: 01 April, 2026**

**Market Snapshot:**

The positive development in the Middle East boosted market sentiment as Nifty50 started the new financial year on a strong note and continued to advance as the day progressed. However, from mid-session, the Index began to pare off its gains and eventually closed at 22,679.40, up by 348 points. Except for the Pharma sector, all segments ended in green, with Defence and Capital Markets being the top performers. Mid and Smallcap indices soared by 2.22% and 3.33%, respectively, outperforming the Frontline Index.

**HOW THE DAY TRENDED**



**INDICES**

Index	Close	Points	%Chg.
Sensex	73134.32	1186.77	<b>1.65</b>
Nifty50	22679.40	348.00	<b>1.56</b>
Nifty Midcap 100	53819.15	1169.15	<b>2.22</b>
Nifty Small Cap 100	15709.80	506.00	<b>3.33</b>

**SECTORAL GAINERS / LOSERS**

Sectors	Close	Points	%Chg.
NIFTY DEFENCE	7597.90	383.60	<b>5.32</b>
NIFTY CAPITAL MKT	4448.40	196.60	<b>4.62</b>
NIFTY PSU BANK	8164.80	291.35	<b>3.70</b>
NIFTY PHARMA	22011.60	(220.65)	<b>(0.99)</b>

**NIFTY TOP GAINERS / LOSERS**

Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
TRENT	3526.50	<b>7.00</b>	DR REDDY	1209.60	<b>(3.61)</b>
INDIGO	4180.80	<b>6.02</b>	HDFC LIFE	572.95	<b>(2.99)</b>
ADANI PORTS	1386.50	<b>5.63</b>	CIPLA	1199.70	<b>(2.00)</b>
ADANI ENT	1842.50	<b>4.76</b>	SUN PHARMA	1728.50	<b>(1.63)</b>

**INDICES LEVELS FOR April 02, 2026**

Nifty (future)		Bank Nifty (future)	
Resistance	23020	Resistance	52230
Support	22600	Support	50900



**PROGRESSIVE'S EVENING STROLL**

**DATE: 01 April, 2026**

**KEY TAKEAWAYS OF THE DAY**

◆ **Defence Ministry signs Rs1,950cr deal with BEL for indigenous mountain radars:**

Ministry of Defence (March 31, 2026) signed a Rs1,950cr contract with Bharat Electronics Limited (BEL) for the procurement of two mountain radars for the Air Force. The Mountain Radar systems have been indigenously designed and developed by the Electronics & Radar Development Establishment under the Defence Research and Development Organisation (DRDO), and will be manufactured by BEL.

◆ **G R Infraprojects secures Rs1,453cr work order from NHAI in Gujarat:**

The company has bagged an order worth Rs1,453.57cr, excluding GST, from National Highways Authority of India (NHAI). The EPC firm stated that it has received Letter of Acceptance (LoA) from NHAI for upgradation of existing two-lane carriageway to four lane divided carriageway in a section of National Highway 56 (NH-56) in Gujarat. The contract is expected to be executed within 910 days from the date of appointment.

◆ **Granules Life Sciences receives VAI classification following USFDA inspection:**

Granules India announced that its wholly owned subsidiary, Granules Life Sciences (GLS), has concluded a recent US FDA inspection of its manufacturing facility at Shamirpet, Telangana, with an inspection classification of Voluntary Action Indicated (VAI). The EIR was issued following a current Good Manufacturing Practice and preapproval inspection (PAI) of the oral solid dosage manufacturing operations conducted between December 15 and 19, 2025. The inspection is now closed, and no regulatory action has been recommended.

◆ **Aurobindo Pharma to consider buyback of equity shares:**

Aurobindo Pharma has scheduled a board meeting for April 6, 2026, to consider a buyback proposal for its fully paid-up equity shares.

◆ **RBL Bank plans to open 200 branches in FY27:**

RBL Bank said it is planning to open 200 branches in FY27 to take its network to over 800 branches. The lender launched 23 new branches across many states on Tuesday to take its overall branch size to over 603. Eyeing the diaspora-related business, the bank said 13 of the 23 newly opened branches are in Keralam.

◆ **Texmaco Rail: Order updates:**

The company has received orders worth Rs413.1mn from South Central Railway for replacement of panel interlocking with electronic interlocking and replacement of outdoor gears and Rs3571.1mn from JSW Group for manufacture and supply of BLSS, BLCS and BFNV rakes alongwith BVCM wagons.

**Source: Media Reports**



#### DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

#### Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

#### Registered Office Address:

Progressive Share Brokers Pvt. Ltd,  
122-124, Laxmi Plaza, Laxmi Indl Estate,  
New Link Rd, Andheri West,  
Mumbai—400053, Maharashtra  
www.progressiveshares.com | Contact No.:022-40777500.

#### Compliance Officer:

Ms. Mamatha Poojari,  
Email: compliance@progressiveshares.com,  
Contact No.:022-40777500.

#### Grievance Officer:

Email: grievancecell@progressiveshares.com

